Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 13Triple Negative Breast Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3NSCLC 2Endometrial Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Neoplasms 1Burkitt Lymphoma 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1Advanced Colorectal Cancer 1

Interventions

Cetuximab 2trifluridine tipiracil drug combination 1regorafenib 1plocabulin 1Oxaliplatin 1N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide 1Irinotecan 1HMPL-013 1Folfox protocol 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Colorectal Cancer × HMPL-013 × Clear all
NCT06199973 2025-07-17

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Active not recruiting
130 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡